<DOC>
	<DOCNO>NCT03050554</DOCNO>
	<brief_summary>The purpose study determine whether avelumab effect cancer body combination SBRT , standard treatment early stage non-small cell lung cancer ( NSCLC ) . Avelumab consider experimental approve United States ( U.S. ) Food Drug Administration ( FDA ) treatment cancer . It type drug call monoclonal antibody ( type protein ) . Monoclonal antibody make recognize , target bind specific proteins cell make tissue . Avelumab design block interaction PD-1 , know immune checkpoint , PD-L1 . By block interaction , immune system may stimulate , allow effectively recognize attack cancer . Stereotactic Body Radiation Therapy ( SBRT ) type radiation use precise target deliver high dose radiation tumor short period time . A positioning cushion Vac-lok use radiation treatment custom make . This custom mold form contours subject body allow proper position comfort stability .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy ( SBRT ) Combined With Avelumab ( Anti-PD-L1 ) Management Early Stage Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This single arm open label Phase I/II study consist two part . In Phase I , investigator assess safety tolerability SBRT combine Avelumab . In Phase II , investigator determine whether SBRT combine Avelumab improves relapse free survival . Subjects Stage I NSCLC undergo surgical resection candidate enrollment . Subjects receive definitive stereotactic body radiation ( SBRT ) 4-5 fraction combine concurrent adjuvant Avelumab 10mg/kg total 6 cycle . Subjects evaluate safety measure occurrence adverse event , serious adverse event , laboratory abnormality . Three blood draw obtain analyze anti-tumor immune response immune correlate .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Tumor ( ) treat ( ) ≤ 5.0 cm ≤250 cm3 Stage I NSCLC deem medically inoperable refuse surgical resection . Life expectancy ≥ 9 month . Acceptable organ marrow function Prior organ transplantation , include allogeneic stem cell transplantation Significant acute chronic infection include : Known history human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) Known history HBV HCV Active autoimmune disease Subjects diabetes type I , vitiligo , psoriasis , hypo hyperthyroid disease require immunosuppressive treatment eligible . Subjects require hormone replacement corticosteroid eligible steroid administer purpose hormonal replacement dos ≤ 10 mg 10 mg equivalent prednisone per day Administration steroid route know result minimal systemic exposure ( topical , intranasal , introocular , inhalation ) acceptable Current use immunosuppressive medication , EXCEPT follow : intranasal , inhale , topical steroid , local steroid injection ( eg , intraarticular injection ) Systemic corticosteroid physiologic dos ≤ 10 mg/day prednisone equivalent Steroids premedication hypersensitivity reaction ( eg , CT scan premedication ) . Cardiovascular disease : cerebral vascular accident/stroke ( &lt; 6 month prior enrollment ) , myocardial infarction ( &lt; 6 month prior enrollment ) , unstable angina , congestive heart failure , serious cardiac arrhythmia require medication . Known severe hypersensitivity reaction monoclonal antibody history anaphylaxis , uncontrolled asthma Pregnancy lactation Known alcohol drug abuse Prior radiotherapy treatment site ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>SBRT</keyword>
	<keyword>Avelumab</keyword>
	<keyword>Stereotactic Body Radiation Therapy</keyword>
	<keyword>radiation</keyword>
	<keyword>NSCLC</keyword>
	<keyword>PD-1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lung</keyword>
</DOC>